Validating therapeutic targets through human genetics
- PMID: 23868113
- DOI: 10.1038/nrd4051
Validating therapeutic targets through human genetics
Abstract
More than 90% of the compounds that enter clinical trials fail to demonstrate sufficient safety and efficacy to gain regulatory approval. Most of this failure is due to the limited predictive value of preclinical models of disease, and our continued ignorance regarding the consequences of perturbing specific targets over long periods of time in humans. 'Experiments of nature' - naturally occurring mutations in humans that affect the activity of a particular protein target or targets - can be used to estimate the probable efficacy and toxicity of a drug targeting such proteins, as well as to establish causal rather than reactive relationships between targets and outcomes. Here, we describe the concept of dose-response curves derived from experiments of nature, with an emphasis on human genetics as a valuable tool to prioritize molecular targets in drug development. We discuss empirical examples of drug-gene pairs that support the role of human genetics in testing therapeutic hypotheses at the stage of target validation, provide objective criteria to prioritize genetic findings for future drug discovery efforts and highlight the limitations of a target validation approach that is anchored in human genetics.
Similar articles
-
The medical and economic roles of pipeline pharmacogenetics: Alzheimer's disease as a model of efficacy and HLA-B(*)5701 as a model of safety.Neuropsychopharmacology. 2009 Jan;34(1):6-17. doi: 10.1038/npp.2008.153. Epub 2008 Oct 15. Neuropsychopharmacology. 2009. PMID: 18923406 Review.
-
The impact of pharmacogenomics research on drug development.Drug Metab Pharmacokinet. 2012;27(1):2-8. doi: 10.2133/dmpk.dmpk-11-rv-093. Epub 2012 Jan 3. Drug Metab Pharmacokinet. 2012. PMID: 22214937 Review.
-
A quantitative framework and strategies for management and evaluation of metabolic drug-drug interactions in oncology drug development: new molecular entities as object drugs.Clin Pharmacokinet. 2010 Nov;49(11):703-27. doi: 10.2165/11536740-000000000-00000. Clin Pharmacokinet. 2010. PMID: 20923246
-
Novelty in the target landscape of the pharmaceutical industry.Nat Rev Drug Discov. 2013 Aug;12(8):575-6. doi: 10.1038/nrd4089. Nat Rev Drug Discov. 2013. PMID: 23903214 No abstract available.
-
Leveraging human genetics to guide drug target discovery.Trends Cardiovasc Med. 2017 Jul;27(5):352-359. doi: 10.1016/j.tcm.2016.08.008. Epub 2016 Aug 26. Trends Cardiovasc Med. 2017. PMID: 27686272 Free PMC article. Review.
Cited by
-
Genetic proxies for therapy of insulin drug targets and risk of osteoarthritis: a drug-target Mendelian randomization analysis.Inflammopharmacology. 2024 Aug 11. doi: 10.1007/s10787-024-01542-8. Online ahead of print. Inflammopharmacology. 2024. PMID: 39127978
-
Stopped clinical trials give evidence for the value of genetics.Nat Genet. 2024 Jul 29. doi: 10.1038/s41588-024-01834-3. Online ahead of print. Nat Genet. 2024. PMID: 39075209 No abstract available.
-
Exome-wide evidence of compound heterozygous effects across common phenotypes in the UK Biobank.Cell Genom. 2024 Jul 10;4(7):100602. doi: 10.1016/j.xgen.2024.100602. Epub 2024 Jun 28. Cell Genom. 2024. PMID: 38944039 Free PMC article.
-
Comprehensive functional characterization of complement factor I rare variant genotypes identified in the SCOPE geographic atrophy cohort.J Biol Chem. 2024 Jul;300(7):107452. doi: 10.1016/j.jbc.2024.107452. Epub 2024 Jun 7. J Biol Chem. 2024. PMID: 38852887 Free PMC article.
-
Sequential immunotherapy: towards cures for autoimmunity.Nat Rev Drug Discov. 2024 Jul;23(7):501-524. doi: 10.1038/s41573-024-00959-8. Epub 2024 Jun 5. Nat Rev Drug Discov. 2024. PMID: 38839912 Review.
References
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources